The results showed that the administration of NF-κB inhibitor JSH-23 reversed EGFRvIII (+)-induced decrease in the expression of PN marker SOX2 and increased the expression of MES marker CD44 in GBM cells compared with the control group (Figure 6B). Here, NFKB1 is linked to glioblastoma.